CITI TRAINING PRACTICE EXAM (SAMPLE)

STUDY GUIDE



SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://cititraining.examzify.com

Table of Contents

Copyright 1

Table of Contents 2

Introduction 3

How to Use This Guide 4

Questions 5

Answers 8

Explanations 10

Next Steps 15

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

Questions

1. What must be provided to investigators before they begin conducting trials?

A. Consent forms

B. Protocol and Investigator's Brochure

C. A list of potential side effects

D. FDA approval letter

2. What type of data may require special handling under HIPAA?

A. Statistical analysis outcomes

B. Protected Health Information (PHI)

C. Sample sizes and methodologies

D. Control group data

3. What is a key ethical principle examined in CITI training?

A. Financial Accountability

B. Respect for persons, beneficence, and justice

C. Transparency in funding sources

D. Data integrity and security

4. What should be done when there are changes to information contained on a signed and dated 1572?

A. File a new 1572 immediately

B. Document the changes in the clinical study records

C. Notify the FDA directly

D. Publish the changes in a medical journal

5. When is it necessary for an investigator to complete and sign a new 1572?

A. Annually

B. At the end of the study

C. When participating in a new protocol added to the IND

D. When the study concludes

6. Which phase aims to examine a drug's short-term risks and preliminary effectiveness?

A. Phase I

B. Phase II

C. Phase III

D. Phase IV

7. Which document is the ICH E6 guideline for good clinical practice directly aligned with?

A. The Constitution of WHO

B. The Declaration of Helsinki

C. The ICH Q9 Quality Risk Management

D. The Good Laboratory Practice (GLP) guidelines

8. In a life-threatening situation without the possibility of obtaining informed consent, what should an investigator do?

A. Proceed without any form of consent

B. Only document the decision in study records

C. The investigator and another physician agree to use the test article and notify the IRB later

D. Wait until consent can be obtained from a legal representative

9. What Form FDA is known as the 'Statement of the Investigator'?

A. 1570

B. 1571

C. 1572

D. 3120

10. What is meant by "mandatory reporting" in the context of CITI training?

A. An option to stop research at any time

B. The obligation to report certain disclosures, such as child abuse or threats of harm

C. A suggestion to maintain confidentiality

D. The formal reporting of research results

Answers

1. B
2. B
3. B
4. B
5. C
6. B
7. B
8. C
9. C
10. B

Explanations

1. What must be provided to investigators before they begin conducting trials?

A. Consent forms

B. Protocol and Investigator's Brochure

C. A list of potential side effects

D. FDA approval letter

The required protocol and Investigator's Brochure must be provided to investigators prior to conducting trials. This information outlines the specific objectives and procedures of the trial, as well as important safety information and potential risks to participants. While consent forms are necessary for participants to review and sign, they do not need to be provided to investigators before the trial begins. A list of potential side effects may be included in the protocol or brochure, but it is not the only information that needs to be provided. FDA approval may be necessary for the trial to begin, but it is not specifically required for investigators to have before conducting the trial.

2. What type of data may require special handling under HIPAA?

A. Statistical analysis outcomes

B. Protected Health Information (PHI)

C. Sample sizes and methodologies

D. Control group data

Protected Health Information (PHI) is any information that can be used to identify an individual and is related to their health condition, the provision of health care, or the payment for health care. Under HIPAA (Health Insurance Portability and Accountability Act), PHI is given particular protection because it contains sensitive information that could lead to privacy breaches if mishandled. This includes names, addresses, birthdates, Social Security numbers, medical records, and any other identifiers that could be linked back to an individual. Because of this sensitive nature, organizations are required to implement stringent safeguards to protect PHI from unauthorized access, use, or disclosure. In contrast, statistical analysis outcomes, sample sizes and methodologies, and control group data generally do not contain identifiable personal information about individuals and thus do not fall under the same requirements for special handling as PHI.

3. What is a key ethical principle examined in CITI training?

A. Financial Accountability

B. Respect for persons, beneficence, and justice

C. Transparency in funding sources

D. Data integrity and security

The key ethical principle examined in CITI training is "Respect for persons, beneficence, and justice." This principle is foundational to research ethics and is derived from the Belmont Report, which outlines ethical guidelines for research involving human subjects. Respect for persons entails recognizing the autonomy and dignity of individuals, ensuring informed consent, and acknowledging the rights of participants. Beneficence refers to the obligation to minimize harm and maximize benefits to participants, emphasizing the welfare of individuals involved in research. Justice includes the fair distribution of both the benefits and burdens of research, ensuring that no specific group of people is exploited or unfairly burdened. Together, these principles form a framework that helps researchers make ethical decisions that prioritize the rights and welfare of participants, uphold the integrity of research, and strengthen public trust in research practices. They guide researchers in navigating complex ethical dilemmas that may arise throughout the research process, highlighting the importance of ethical considerations in human subjects research.

4. What should be done when there are changes to information contained on a signed and dated 1572?

A. File a new 1572 immediately

B. Document the changes in the clinical study records

C. Notify the FDA directly

D. Publish the changes in a medical journal

When there are changes to information contained on a signed and dated 1572, the correct course of action is to document these changes in the clinical study records. This is because the 1572 is a legal contract and should be kept as a historical document. Filing a new 1572 could potentially cause confusion and does not accurately reflect the changes that have been made. Notifying the FDA directly or publishing the changes in a medical journal are not necessary as long as the changes are properly documented in the study records.

5. When is it necessary for an investigator to complete and sign a new 1572?

A. Annually

B. At the end of the study

C. When participating in a new protocol added to the IND

D. When the study concludes

The 1572 is a form used by clinical investigators to indicate their agreement to follow certain procedures and regulations while conducting a clinical study. It is necessary for an investigator to complete and sign a new 1572 when participating in a new protocol added to the investigational new drug (IND) application. This is because the new protocol may have different procedures and regulations that the investigator needs to agree to. The other options, such as annually, at the end of the study, or when the study concludes, would not be accurate as they do not specifically address when a new protocol is added to the study. It is important for the investigator to review and sign a new 1572 in order to ensure that they are aware of and complying with all necessary procedures and regulations for the new protocol.

6. Which phase aims to examine a drug's short-term risks and preliminary effectiveness?

A. Phase I

B. Phase II

C. Phase III

D. Phase IV

Phase II aims to examine a drug's short-term risks and preliminary effectiveness. During this phase, the drug is tested on a larger group of people, typically 100-300, to gather more data on its safety and effectiveness. Phase II also helps to determine the optimal dosage of the drug. A) Phase I tests a drug on a small group of healthy volunteers and focuses on its safety and potential side effects. C) Phase III tests the drug on a larger group of patients to further evaluate its effectiveness and safety, as well as compare it to current treatments. D) Phase IV, also known as post-marketing surveillance, is conducted after the drug has been approved for use and aims to evaluate long-term side effects and effectiveness. Therefore, none of these phases are focused solely on short-term risks and preliminary effectiveness, making them incorrect options.

7. Which document is the ICH E6 guideline for good clinical practice directly aligned with?

A. The Constitution of WHO

B. The Declaration of Helsinki

C. The ICH Q9 Quality Risk Management

D. The Good Laboratory Practice (GLP) guidelines

The ICH E6 guideline for good clinical practice is directly aligned with the Declaration of Helsinki. This is because the Declaration of Helsinki is an internationally accepted ethical standard for conducting medical research on human subjects, which is the focus of the ICH E6 guideline. The other options, such as the Constitution of WHO and the GLP guidelines, may have some overlap with the principles of good clinical practice, but they are not directly aligned with the ICH E6 guideline. Additionally, the ICH Q9 Quality Risk Management is a separate guideline that focuses on risk management in the pharmaceutical industry, rather than ethics in clinical trials. Therefore, the Declaration of Helsinki is the best option that aligns with the ICH E6 guideline.

8. In a life-threatening situation without the possibility of obtaining informed consent, what should an investigator do?

A. Proceed without any form of consent

B. Only document the decision in study records

C. The investigator and another physician agree to use the test article and notify the IRB later

D. Wait until consent can be obtained from a legal representative

In a life-threatening situation where obtaining informed consent is not possible, the investigator and another physician may agree to use the test article and notify the IRB later. This is the most ethical course of action in this situation because it allows for the potential benefit of the test article to be used in emergency situations while still adhering to ethical guidelines. Choosing option A would violate ethical principles and potentially harm the subject. Option B may be insufficient and not fulfill the necessary requirements for proper documentation. Option D may not be feasible in a time-sensitive and life-threatening situation.

9. What Form FDA is known as the 'Statement of the Investigator'?

A. 1570

B. 1571

C. 1572

D. 3120

The Form FDA known as the 'Statement of the Investigator' is Form 1572. This form is used by the Food and Drug Administration to document that a clinical investigator has agreed to follow all of the study protocols and regulations. Option A, Form 1570, is not a form recognized by the FDA and therefore is incorrect. Option B, Form 1571, is used for reporting adverse events during clinical trials and is not the same as the Statement of the Investigator. Option D, Form 3120, is a form used for requesting an export certificate for medical products and is unrelated to clinical trials. Therefore, the correct option is C, Form 1572, which is specifically used for documenting the agreement between the clinical investigator and the FDA.

10. What is meant by "mandatory reporting" in the context of CITI training?

A. An option to stop research at any time

B. The obligation to report certain disclosures, such as child abuse or threats of harm

C. A suggestion to maintain confidentiality

D. The formal reporting of research results

In the context of CITI training, "mandatory reporting" refers to the legal and ethical obligation to report certain disclosures that may involve the safety and welfare of individuals, particularly vulnerable populations such as children. This obligation arises in specific situations, such as when there is evidence or reasonable suspicion of child abuse or neglect, or when an individual poses a credible threat of harm to themselves or others. This reporting requirement is essential in protecting individuals from potential harm and ensuring that appropriate actions can be taken by the relevant authorities or organizations. It underscores the importance of ethical responsibilities that researchers and professionals have toward their subjects and society, ensuring that critical information is communicated to safeguard those at risk. In contrast, options that imply stopping research at any time, suggestions for maintaining confidentiality, or formal reporting of research results do not accurately capture the essence of mandatory reporting as it relates to protective laws and ethical standards designed to prevent harm.

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://cititraining.examzify.com

We wish you the very best on your exam journey. You've got this!